{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2698080"],"location":["China"],"study_start_month":["10"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Mechanism exploration and clinical verification of new integrated markers of capecitabine clinical effect","description":"Interventions: Capecitabine:Nil;Capecitabine + Bevacizumab/ Cetuximab:Nil;Capecitabine + Oxaliplatin:Nil;Capecitabine + Oxaliplatin + Bevacizumab/Cetuximab:Nil;Capecitabine + radiotherapy:Nil;Irinotecan + capecitabine:Nil\nPrimary outcome(s): Three-year disease-free survival\nStudy Design: Non randomized control","dates":{"creation":"2020-10-15"},"accession":"2698080","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000037696"]}}